As suggested by the preclinical pharmacodynamic studies (JMT-Bio Inc., unpublished data, 2020), JMT103 (at the doses of 2.5 mg/kg and 25 mg/kg) can significantly reduce bone resorption biomarkers of type I collagen carboxyl terminal peptide (β-CTx) and tartrate-resistant acid phosphatase 5b (TRAP5b) in aged female rhesus monkey models of osteoporosis, increase bone mineral density (BMD) in ovariectomized rhesus monkey models of osteoporosis, and significantly reduce serum calcium concentration in both of the models. The gene discussed is ACP5; the disease is osteoporosis.